BCL2 inhibitors and MCL1 inhibitors for hematological malignancies.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020006785
Abstract: BCL2 and MCL1 are commonly expressed pro-survival (anti-apoptotic) proteins in hematological cancers and play important roles in their biology either through dysregulation or by virtue of intrinsic importance to the cell-of-origin of the malignancy. A… read more here.
Keywords: bcl2 inhibitors; mcl1 inhibitors; bh3 mimetics; inhibitors mcl1 ... See more keywords